(R,S)-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R,S)-2-amino-4-oxo-4-(3',4'-dichlorophenyl)-butanoic acid
• 英文别名: PNU 156561A；2-amino-4-(3',4'-dichlorophenyl)-4-oxo-butyric acid；2-Amino-4-(3,4-dichloro-phenyl)-4-oxo-butyric acid；2-amino-4-(3,4-dichlorophenyl)-4-oxobutanoic acid
• 化学式: C₁₀H₉Cl₂NO₃
• 分子量: 262.092
• InChiKey: MXBKZYGNMKXYQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES
  申请人：——

  公开号：US20010008947A1

  公开（公告）日：2001-07-19

  Use in the prevention and/or in the treatment of neurodegenerative diseases of 2-amino-4-phenyl-4-oxo-butyric acid derivatives which act as kynureninase enzyme inhibitors and/or kynurenine-3-hydroxylase enzyme inhibitors. Several of these derivatives are new and, as such, constitute a further object of this invention, together with the process for their preparation and the pharmaceutical compositions containing them.

  利用2-氨基-4-苯基-4-羟基丁酸衍生物在神经退行性疾病的预防和/或治疗中，这些衍生物作为酮喹啉酸酶抑制剂和/或酮喹啉-3-羟化酶抑制剂。其中一些衍生物是新的，因此构成本发明的另一目标，包括其制备过程以及含有它们的药物组合物。
• 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES WITH KYNURENINASE AND/OR KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY
  申请人：PHARMACIA S.p.A.

  公开号：EP0662948A1

  公开（公告）日：1995-07-19
• N-SUBSTITUTED-2-AMINO-4-PHENYL-4-OXO-BUTANOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITORY ACTIVITY
  申请人：PHARMACIA & UPJOHN S.p.A.

  公开号：EP0931056A1

  公开（公告）日：1999-07-28
• TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS
  申请人：Psychogenics Inc.

  公开号：EP2858649B1

  公开（公告）日：2019-10-23
• Treatment of Motor and Movement Disorder Side Effects Associated with Parkinson's Disease Treatments
  申请人：Psychogenics, Inc.

  公开号：US20180250295A1

  公开（公告）日：2018-09-06

  This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.